Called Neffy, it offers a needle-free alternative to the EpiPen used by those at risk of potentially fatal anaphylaxis to inject themselves with adrenaline.

Alnylam Pharmaceuticals Inc. ALNY) on Thursday reported third-quarter net income of $251.1 million, after reporting a loss in the same period a year earlier.

CREATE Medicines, Inc. (formerly Myeloid Therapeutics) today announced new preclinical data for RetroT, the company's fully ...

A former Cambridge city employee sentenced to life imprisonment for fatally stabbing an unarmed man over what prosecutors ...

The early-stage pipeline for amyotrophic lateral sclerosis drugs exploded last year. After ALS R&D notched 28 new trial ...

A year after Boston's inclusionary zoning policy was made more aggressive, developers and politicians have criticized it for ...

A Canadian’s plan to bring his late celebrity wife back to life in AI form has raised a host of ethical questions about prolonging human existence in the digital universe. Alan Hamel, a Canadian ...

Work on an immense incinerator in Wisbech, Cambs is due to start in just days and locals are dreading the ear-splitting noise ...

President Trump’s sweeping legislation is bringing dramatic changes to Medicaid, SNAP, and other government programs — and ...

Zhang Xin rose from poverty to become a self-made billionaire dubbed “the woman who built Beijing” by building a property ...

Rob Edwards’ journey has taken him from teenage prodigy at Carlisle United, to stints at Bristol City, Preston and Exeter and ...

Cannabix Technologies Inc. (the "Company or Cannabix") is pleased to report that the United States Patent and Trademark Office (USPTO) has granted patent No. 18/1729,658 entitled, "Contact-Free Breath ...